Dr. Mayo will talk about studies involving animal-to-human translational work highlighting how endocannabinoid function regulates stress reactivity and fear learning, leveraging human behavioral pharmacology and neuroimaging. She will also highlight outcomes from a recent clinical trial exploring how augmenting cannabinoid function impacts clinical, behavioral, and neural measures in people with PTSD.